Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
NCT06021977Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Started Sep 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT06021977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021977.